4/13
06:00 am
huma
Humacyte (HUMA) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Neutral
Report
Humacyte (HUMA) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
4/11
01:00 am
huma
Low
Report
4/9
04:00 pm
huma
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? [TheStreet.com]
Medium
Report
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? [TheStreet.com]
4/9
03:50 pm
huma
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Low
Report
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
4/8
11:46 am
huma
Humacyte (HUMA) had its price target lowered by Barclays PLC from $3.50 to $1.50. They now have an "overweight" rating on the stock.
Low
Report
Humacyte (HUMA) had its price target lowered by Barclays PLC from $3.50 to $1.50. They now have an "overweight" rating on the stock.
3/31
11:27 am
huma
Humacyte (HUMA) had its "speculative buy" rating reaffirmed by Benchmark Co.. They now have a $1.00 price target on the stock, down from $10.00.
Low
Report
Humacyte (HUMA) had its "speculative buy" rating reaffirmed by Benchmark Co.. They now have a $1.00 price target on the stock, down from $10.00.
3/30
02:17 pm
huma
Humacyte (HUMA) had its price target lowered by Piper Sandler from $3.00 to $1.00. They now have a "neutral" rating on the stock.
Medium
Report
Humacyte (HUMA) had its price target lowered by Piper Sandler from $3.00 to $1.00. They now have a "neutral" rating on the stock.
3/30
09:22 am
huma
Humacyte (HUMA) had its price target lowered by TD Cowen from $3.50 to $1.00. They now have a "buy" rating on the stock.
High
Report
Humacyte (HUMA) had its price target lowered by TD Cowen from $3.50 to $1.00. They now have a "buy" rating on the stock.
3/29
04:53 pm
huma
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity [Yahoo! Finance]
High
Report
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity [Yahoo! Finance]
3/27
02:24 pm
huma
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
3/27
10:57 am
huma
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/27
10:50 am
huma
Humacyte (HUMA) had its price target lowered by BTIG Research from $6.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
Humacyte (HUMA) had its price target lowered by BTIG Research from $6.00 to $3.00. They now have a "buy" rating on the stock.
3/27
10:13 am
huma
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
3/27
07:55 am
huma
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/27
07:00 am
huma
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
High
Report
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
3/26
08:00 am
huma
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Medium
Report
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
3/23
11:24 pm
huma
Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy? [Yahoo! Finance]
Medium
Report
Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy? [Yahoo! Finance]
3/23
11:02 am
huma
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]
Medium
Report
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]
3/23
08:00 am
huma
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
Medium
Report
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
3/20
08:22 am
huma
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]
Low
Report
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]
3/19
08:31 am
huma
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
High
Report
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
3/19
08:30 am
huma
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
High
Report
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
3/17
08:43 am
huma
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
3/17
08:29 am
huma
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
Low
Report
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
3/17
08:00 am
huma
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
Low
Report
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair